Drug Type Trispecific antibody |
Synonyms |
Target |
Mechanism LILRB1 inhibitors(Leukocyte immunoglobulin-like receptor B1 inhibitors), LILRB2 inhibitors(Leukocyte immunoglobulin-like receptor subfamily B member 2 inhibitors), LILRB3 modulators(Leukocyte Ig-like receptor-3 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | US | 22 Mar 2024 |